• Trinity Biotech received a European patent covering blood pressure-related metrics for its PrePsia early preeclampsia prediction platform.
• The PrePsia portfolio now totals nine granted patents across Europe and the U.S.
• The test is being developed for early screening of pregnancies at increased risk of preterm preeclampsia.
• Launch is planned through its New York State Department of Health-approved reference laboratory.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608281715PRIMZONEFULLFEED9817933) on August 28, 2026, and is solely responsible for the information contained therein.